C5 inhibitors are estimated at 46.0% by drug class in 2026, with PNH projected at 34.0% and hospitals at 41.0%. Approval expansion supports broader specialist use, while infection controls and reimbursement reviews delay treatment initiation.
Complement Inhibitors Market Analysis By ApplicationComplement Inhibitors Market Analysis By Distribution ChannelComplement Inhibitors Market Analysis By End UserComplement Inhibitors Market Analysis By Route Of AdministrationComplement Inhibitors Market Breakdown By Drug Class, Application, And RegionComplement Inhibitors Market Opportunity Matrix Growth Vs Value